Latex Agglutination Test Kits Market Size, Share & Trends Analysis Report By Product Type (ELISA, Indirect Fluorescent), By Test Type (Antibody Detection), By Sample Type (Blood), By End-use, By Region, And Segment Forecasts, 2024 - 2030

Latex Agglutination Test Kits Market Size, Share & Trends Analysis Report By Product Type (ELISA, Indirect Fluorescent), By Test Type (Antibody Detection), By Sample Type (Blood), By End-use, By Region, And Segment Forecasts, 2024 - 2030


Latex Agglutination Test Kits Market Growth & Trends

The global latex agglutination test kits market size is expected to reach USD 934.77 million by 2030 and is projected to grow at a CAGR of 5.65% from 2024 to 2030, according to a new report by Grand View Research, Inc. The surge in infectious and chronic diseases such as rheumatoid arthritis, increasing demand for point-of-care testing, coupled with rising awareness are the key factors boosting the market. Furthermore, increasing investment in R&D activities as well as the growing initiatives by the key players are anticipated to offer lucrative opportunities for the market over the forecast period.

Latex agglutination test kits market is driven by the rising prevalence of infectious and autoimmune diseases. These tests are readily available and play a crucial role in the diagnosis of diseases such as tuberculosis, hepatitis, meningitis, Haemophilus influenza, typhoid, and pneumonia. For instance, according to the WHO, in 2021, an estimated 10.6 million individuals were affected with tuberculosis globally. Additionally, autoimmune conditions such as lupus and rheumatoid arthritis are on the rise. The availability of specialized kits like SLE Latex agglutination and Waaler Rose latex test kits is contributing to this growth. These tests offer rapid diagnostic capabilities, addressing the urgent healthcare needs associated with infectious and autoimmune diseases. The market expansion is further driven by the demand for accurate and swift diagnostic methods in the face of these healthcare challenges.

These kits offer several advantages such as, eliminates the need for waiting to interpret test results and helps in efficient patient care. In addition, it significantly reduces the cost of diagnosis and contributes to timely treatment decisions, especially in regions with limited laboratory infrastructure and resource constraints. The growing trend of decentralized testing has played a crucial role in driving the global adoption of these products. Thus, the numerous benefits provided by these tests are key factors contributing to their increasing adoption across the globe.

However, the emergence of reliable and novel alternate diagnostic tests, especially in developed economies such as U.S. and UK are anticipated to hamper the market over the forecast period. In addition, the limitations such as cross reactivity & standardization of the kits and technological advancements in point-of-care device for the diagnosis of infectious in various settings including hospitals and clinics many impede the market to certain extent during the study period.

Latex Agglutination Test Kits Market Report Highlights
  • ELISA segment dominated the latex agglutination test kits market in 2023 owing to the high prevalence of the disease and increasing R&D activities and growing investments for the diagnosis of diseases
  • By test type, antibody detection segment held the largest segment share of the latex agglutination test kits market 2023, attributable to their high specificity and sensitivity
  • Blood segment held the largest segment share of the latex agglutination test kits market in 2023, attributable to their reliability and accuracy in disease diagnosis
  • By end-use, the hospital pharmacies segment held the largest share of latex agglutination test kits market in 2023. This growth can be attributed to numerous factors, including easy accessibility of these products through hospital pharmacies
  • North America has established a strong regional position with a 42.97% share in 2023, owing to the increasing funding for development of novel diagnostics, high disposable income, technological advancements, and presence of key operating players in the region
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. COMMODITY FLOW ANALYSIS
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Rising prevalence of infectious and autoimmune diseases
3.4.2. Increasing demand for point-of-care testing (POCT)
3.4.3. Growing R&D activities
3.5. Market Restraint Analysis
3.5.1. Emergence of reliable and novel diagnostics
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Product Type Business Analysis
4.1. Latex Agglutination Test Kits market: Product Type Movement Analysis
4.2. ELISA
4.2.1. ELISA Market, 2018 - 2030 (USD Million)
4.3. Indirect Fluorescent
4.3.1. Indirect Fluorescent Market, 2018 - 2030 (USD Million)
4.4. Hemagglutination Inhibition
4.4.1. Hemagglutination Inhibition Market, 2018 - 2030 (USD Million)
4.5. Serum Neutralization
4.5.1. Serum Neutralization Inhibition Market, 2018 - 2030 (USD Million)
Chapter 5. Test Type Business Analysis
5.1. Latex Agglutination Test Kits Market: Test Type Movement Analysis
5.2. Antibody Detection
5.2.1. Antibody Detection Market, 2018 - 2030 (USD Million)
5.3. Antigen Testing
5.3.1. Antigen Testing Market, 2018 - 2030 (USD Million)
Chapter 6. Sample Type Business Analysis
6.1. Latex Agglutination Test Kits Market: Sample Type Movement Analysis
6.2. Blood
6.2.1. Blood Market, 2018 - 2030 (USD Million)
6.3. Urine
6.3.1. Urine Market, 2018 - 2030 (USD Million)
6.4. Cerebrospinal Fluid
6.4.1. Cerebrospinal Fluid Market, 2018 - 2030 (USD Million)
6.5. Others
6.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. End-use Business Analysis
7.1. Latex Agglutination Test Kits Market: Distribution Channel Movement Analysis
7.2. Hospital Pharmacies
7.2.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
7.3. Retail Pharmacies
7.3.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
7.4. Online Pharmacies
7.4.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Latex Agglutination Test Kits Market Share By Region, 2023 & 2030
8.2. North America
8.2.1. North America Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Target Disease Prevalence
8.2.2.3. Competitive Scenario
8.2.2.4. Regulatory Framework
8.2.2.5. Reimbursement Scenario
8.2.2.6. U.S. Latex Agglutination Test Kits market, 2018 - 2030 (USD MILLION)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. Canada Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Target Disease Prevalence
8.3.2.3. Competitive Scenario
8.3.2.4. Regulatory Framework
8.3.2.5. Reimbursement Scenario
8.3.2.6. Germany Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. UK Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. France Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. Italy Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Spain Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Denmark Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Sweden Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Norway Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Competitive Scenario
8.4.2.4. Regulatory Framework
8.4.2.5. Reimbursement Scenario
8.4.2.6. Japan Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. China Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. India Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. South Korea Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.4.6. Australia
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. Australia Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Thailand Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Competitive Scenario
8.5.2.4. Regulatory Framework
8.5.2.5. Reimbursement Scenario
8.5.2.6. Brazil Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Mexico Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Argentina Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.6. MEA
8.6.1. MEA Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Competitive Scenario
8.6.2.4. Regulatory Framework
8.6.2.5. Reimbursement Scenario
8.6.2.6. South Africa Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. Saudi Arabia Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. UAE Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. Kuwait Latex Agglutination Test Kits market, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Latex Agglutination Test Kits market Share Analysis, 2023
9.3.3. Company Profiles
9.3.3.1. Eurofins Abraxis
9.3.3.1.1. Company Overview
9.3.3.1.2. Financial Performance
9.3.3.1.3. Product Benchmarking
9.3.3.1.4. Strategic Initiatives
9.3.3.2. Thermo Fisher Scientific Inc.
9.3.3.2.1. Company Overview
9.3.3.2.2. Financial Performance
9.3.3.2.3. Product Benchmarking
9.3.3.2.4. Strategic Initiatives
9.3.3.3. bioMérieuxSA
9.3.3.3.1. Company Overview
9.3.3.3.2. Financial Performance
9.3.3.3.3. Product Benchmarking
9.3.3.3.4. Strategic Initiatives
9.3.3.4. Bioloegend Inc.
9.3.3.4.1. Company Overview
9.3.3.4.2. Financial Performance
9.3.3.4.3. Product Benchmarking
9.3.3.4.4. Strategic Initiatives
9.3.3.5. HiMedia Laboratories Microbiology International
9.3.3.5.1. Company Overview
9.3.3.5.2. Financial Performance
9.3.3.5.3. Product Benchmarking
9.3.3.5.4. Strategic Initiatives
9.3.3.6. Biotium
9.3.3.6.1. Company Overview
9.3.3.6.2. Financial Performance
9.3.3.6.3. Product Benchmarking
9.3.3.6.4. Strategic Initiatives
9.3.3.7. Creative Diagnostics
9.3.3.7.1. Company Overview
9.3.3.7.2. Financial Performance
9.3.3.7.3. Product Benchmarking
9.3.3.7.4. Strategic Initiatives
9.3.3.8. Bio-Rad Laboratories, Inc.
9.3.3.8.1. Company Overview
9.3.3.8.2. Financial Performance
9.3.3.8.3. Product Benchmarking
9.3.3.8.4. Strategic Initiatives
9.3.3.9. Cardinal Health
9.3.3.9.1. Company Overview
9.3.3.9.2. Financial Performance
9.3.3.9.3. Product Benchmarking
9.3.3.9.4. Strategic Initiatives
9.3.3.10. Atlas Medical GmbH
9.3.3.10.1. Company Overview
9.3.3.10.2. Financial Performance
9.3.3.10.3. Product Benchmarking
9.3.3.10.4. Strategic Initiatives
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Disease Type/Drug Class Launch
9.3.4.5. Partnerships
9.3.4.6. Others

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings